A
ABL Bio Inc
KOSDAQ:298380
ABL Bio Inc
KOSDAQ:298380
Price:
34 450
KRW
2.23%
Market Closed
Market Cap:
1.7T
KRW
ABL Bio Inc
Tax Provision
|
ABL Bio Inc
Tax Provision Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
Latest Figures & CAGR of Competitors
| Company | Tax Provision | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
A
|
ABL Bio Inc
KOSDAQ:298380
|
Tax Provision
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Celltrion Inc
KRX:068270
|
Tax Provision
-₩157.2B
|
CAGR 3-Years
-1%
|
CAGR 5-Years
-14%
|
CAGR 10-Years
-17%
|
|
|
SK Bioscience Co Ltd
KRX:302440
|
Tax Provision
₩39B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
H
|
Hugel Inc
KOSDAQ:145020
|
Tax Provision
-₩22B
|
CAGR 3-Years
8%
|
CAGR 5-Years
-3%
|
CAGR 10-Years
N/A
|
|
|
P
|
PharmaResearch Co Ltd
KOSDAQ:214450
|
Tax Provision
-₩26.9B
|
CAGR 3-Years
-43%
|
CAGR 5-Years
-49%
|
CAGR 10-Years
-28%
|
|
|
Alteogen Inc
KOSDAQ:196170
|
Tax Provision
₩24.1B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
65%
|
|
ABL Bio Inc
Glance View
ABL Bio, Inc. engages in the development of therapeutic drugs for immuno-oncology and neurodegenerative diseases. The company is headquartered in Seongnam, Gyeonggi-Do. The company went IPO on 2018-12-19. The major products include anti-angiogenesis antibodies anti-tumor targeting antibodies, T cell engager bispecific antibodies (TCEs), dual immune cell targeting bispecific antibodies (DICs), novel immune cell targeting antibodies (NICs), brain disease dual antibodies, antibody-drug conjugates (ADCs) , among others.
Intrinsic Value
9 630.52
KRW
Overvaluation 72%
A
You don't have any saved screeners yet